Loading...
Overall survival, costs, and healthcare resource use by line of therapy in Medicare patients with newly diagnosed metastatic urothelial carcinoma
AIMS: Medicare patients with metastatic or surgically unresectable urothelial carcinoma (mUC) often receive platinum-based chemotherapy as first line of therapy (LOT) but invariably progress, requiring additional LOTs and healthcare resource use (HCRU). To better understand the evolving mUC treatmen...
Na minha lista:
| Udgivet i: | J Med Econ |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7384456/ https://ncbi.nlm.nih.gov/pubmed/30836812 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/13696998.2019.1591424 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|